LY3819469

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyLipoprotein DisorderRenal Insufficiency

Phase 1

A Study of LY3819469 in Healthy Participants

CompletedNCT04914546

Eli Lilly and CompanyHealthy

Start: 2021-06-14End: 2022-11-09Updated: 2022-11-21

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

CompletedNCT05841277

Eli Lilly and CompanyHealthy, Renal Insufficiency

Start: 2023-04-25End: 2024-01-09Updated: 2024-03-29

A Study to Compare Two Formulations of LY3819469 in Healthy Participants

CompletedNCT05932446

Eli Lilly and CompanyHealthy

Start: 2023-06-30End: 2023-11-07Updated: 2024-01-05

Phase 2

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

CompletedNCT05565742

Eli Lilly and CompanyLipoprotein Disorder

Start: 2022-10-20End: 2024-10-17Updated: 2025-05-28

Related Papers

Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a).

2026-08-31

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)

New England Journal of Medicine2025-03-3059 citations

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)

JAMA2023-11-12168 citations